Akero Therapeutics Reports Encouraging 36-Week Analysis of 9

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

22% and 24% of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo 4% of patients in each EFX dose group...

Related Keywords

United States , Americans , Sarah Oconnell , Andrew Cheng , Pa Fibroscan , Stephen Harrison , Austin Murtagh , Linkedin , Nasdaq , Akero Therapeutics Inc , Twitter , Pinnacle Clinical Research , Exchange Commission , Liver Biopsy Analysis Set , Non Invasive Markers , Change From Baseline , Full Analysis , Serum Markers , Conference Call , South San , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Markets ,